Drugs / BN201
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03630497 | May 2018 → Feb 2019 | optic neuritis | Accure Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07623668 | May 2026 → Dec 2027 expected | optic neuritis | Oculis | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BN201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03630497 ↗ |
| Known as | OCS-05 | “Privosegtor (OCS-05) 3 mg/kg/day IV for 5 treatment days” NCT07623668 ↗ |
| Known as | Privosegtor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07623668 ↗ |
| Route | Intravenous | “single intravenous doses of BN201” NCT03630497 ↗ |